Skip to main content

August 2013 Vol 6, No 6 Special Issue

Practice Management

FDA Expected to Approve Surrogate End Point for Neoadjuvant Breast Cancer Trials

Caroline Helwick

Lung Cancer, Oncology

Crizotinib Superior to Standard Chemotherapy in ALK-Positive Lung Cancer

Xofigo (Radium Ra 223 Dichloride): The First Alpha Particle–Emitting Radioactive Agent for the Treatment of Castration-Resistant Prostate Cancer with Symptomatic Bone Metastases

Lisa A. Raedler, PhD, RPh

Cancer Care in 2013: Hope, Reality, and a Call to Action

Gary M. Owens, MD

Experts Debate Value of Bevacizumab in Newly Diagnosed Glioblastoma

Bevacizumab an Effective New Treatment Option for Relapsed Cervical Cancer

Sorafenib Effective in Metastatic Differentiated Thyroid Cancer

Prostate Cancer

New Analysis Confirms Radium Ra-223 Prolongs Survival in Patients with Metastatic CRPC, Regardless of Previous Docetaxel Therapy Status

Prostate Cancer

Lack of Knowledge Prevents Men with Early-Stage Prostate Cancer from Choosing Active Surveillance

Breast Cancer, Oncology

New Data Confirm Benefits of 10 Years Tamoxifen versus 5 Years in Patients with ER-Positive Breast Cancer

Page 1 of 4
Results 1 - 10 of 34